scholarly journals The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes

Aging ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 4794-4814 ◽  
Author(s):  
Elisabet Cuyàs ◽  
Juan Gumuzio ◽  
Sara Verdura ◽  
Joan Brunet ◽  
Joaquim Bosch-Barrera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Breast Cancer Subtypes ◽  
Epigenetic Therapy ◽  
Breast Cancer Stem Cells ◽  
Her2 Positive ◽  
Cancer Subtypes ◽  
Luminal B ◽  
Positive Breast Cancer

Abstract 3029: MKP1-mediated survival of HER2 positive breast cancer stem cells

2014 ◽  
Author(s):  
Demet Candas ◽  
Chung-Ling Lu ◽  
Ming Fan ◽  
Frank Chuang ◽  
Colleen Sweeney ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Breast Cancer Stem Cells ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Role of d16HER2 in HER2-positive breast cancer stem cells

2016 ◽  
Vol 61 ◽  
pp. S42
Author(s):  
L. Castagnoli ◽  
G.C. Ghedini ◽  
A. Koschorke ◽  
C. Chiodoni ◽  
P. Nanni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Breast Cancer Stem Cells ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker

Tumor Biology ◽  
2016 ◽  
Vol 37 (11) ◽  
pp. 14757-14764 ◽  
Author(s):  
Bo Lei ◽  
Xian-yu Zhang ◽  
Jia-peng Zhou ◽  
Guan-nan Mu ◽  
Yi-wen Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Prognostic Marker ◽  
Transcriptome Sequencing ◽  
Breast Cancer Stem Cells ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Doxycycline targets aldehyde dehydrogenase‑positive breast cancer stem cells

2018 ◽  
Author(s):  
Chang‑Ching Lin ◽  
Miao‑Chia Lo ◽  
Rebecca Moody ◽  
Nicholas Stevers ◽  
Samantha Tinsley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Aldehyde Dehydrogenase ◽  
Breast Cancer Stem Cells ◽  
Positive Breast Cancer

scholarly journals PPARγ maintains ERBB2-positive breast cancer stem cells

Oncogene ◽  
2013 ◽  
Vol 32 (49) ◽  
pp. 5512-5521 ◽  
Author(s):  
X Wang ◽  
Y Sun ◽  
J Wong ◽  
D S Conklin
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Breast Cancer Stem Cells ◽  
Positive Breast Cancer

scholarly journals Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib

2020 ◽  
pp. 1-12
Author(s):  
Saranya Chumsri ◽  
Amanda Schech ◽  
Angela Brodie ◽  
Jane Lewis ◽  
Katherine Tkaczuk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Phase I ◽  
Single Agent ◽  
Preclinical Studies ◽  
Her2 Positive ◽  
Mesenchymal Transition ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Purpose: Considerable preclinical and clinical data indicate that only a small subset of tumor cells has longterm proliferating capacity. These cells are termed cancer stem cells (CSCs). Failure to eradicate CSCs is hypothesized to be a cause of cancer recurrence after potentially curative therapies. Therefore, approaches that target CSCs have the potential to improve outcomes. We evaluated the combination of vorinostat and lapatinib to target CSCs and metastasis. Experimental Design: We conducted preclinical studies and a phase I/II clinical trial to determine the effects of vorinostat and lapatinib to CSCs. Results: Our preclinical studies demonstrated that vorinostat and lapatinib further reduced CSCs compared to either single agent. Reduction in self-renewal proteins, mammospheres, epithelial-mesenchymal transition (EMT) markers, and cell migration was also observed. Based on these findings, the combination was evaluated in the phase I trial to which a total of 12 patients were enrolled. Dose-limiting toxicity was not observed in phase I, and the recommended phase II dose was vorinostat 400 mg 4 days on 3 days off and lapatinib 1,250 mg daily. In HER2-positive breast cancer patients, the clinical benefit rate was observed in 43% of subjects. Interestingly, patients who remained on vorinostat and lapatinib did not develop any new site of metastasis. Conclusion: The combination of vorinostat and lapatinib is safe and active in HER2-positive breast cancer. Further studies are needed to evaluate this strategy to target CSCs and metastasis.

Sign in / Sign up

Export Citation Format

Share Document